Zebrafish Cardiac Hypertrophy Models

Introduction

Cardiac hypertrophy is an adaptive increase in heart size that occurs in response to increased workload, neurohormonal stimulation, sarcomere gene defects, anemia, hypertension, or valvular disease. Although early hypertrophy can help maintain cardiac output, persistent or pathological hypertrophy is associated with cardiomyocyte enlargement, altered sarcomere organization, fibrosis, impaired relaxation, arrhythmia, and eventual heart failure. Clinically, patients may present with dyspnea, exercise intolerance, chest discomfort, palpitations, syncope, or signs of diastolic dysfunction. Cardiac hypertrophy is common in patients with hypertension, hypertrophic cardiomyopathy, chronic anemia, metabolic disease, and aging-related cardiovascular disorders.

Current treatments depend on the underlying cause and include blood pressure control, β-blockers, calcium channel blockers, renin–angiotensin–aldosterone system modulation, anti-arrhythmic therapy, and disease-specific interventions. However, mechanisms that distinguish adaptive from maladaptive hypertrophy remain incompletely defined. Zebrafish models provide an in vivo platform to study cardiac growth, cardiomyocyte hypertrophy and hyperplasia, sarcomere-related cardiomyopathy, diastolic dysfunction, and arrhythmia susceptibility. These models are useful for target validation, pathway analysis, and screening of compounds that reduce pathological cardiac remodeling.

Why Zebrafish?

• Zebrafish allow in vivo analysis of cardiac size, structure, and function.
• Larval models support rapid imaging-based phenotypic screening.
• Adult models capture workload-induced cardiac remodeling.
• Conserved cardiac genes support translational mechanism studies.

Available Zebrafish Disease Models

Phenotypic Evaluation

Key Applications

• Anti-hypertrophic compound evaluation: Assess whether candidate compounds reduce heart enlargement, ventricular wall thickening, cardiomyocyte hypertrophy, or remodeling-related gene expression.
• Hypertrophic cardiomyopathy target validation: Evaluate the role of sarcomere genes, calcium-handling regulators, metabolic pathways, and stress-response signaling in HCM-like phenotypes.
• Cardiac remodeling mechanism studies: Investigate how workload, anemia, neurohormonal stimulation, or genetic defects drive adaptive versus pathological cardiac growth.
• Functional assessment of disease severity: Quantify the relationship between structural hypertrophy, diastolic dysfunction, contractility changes, and arrhythmia-related endpoints.
• Screening of cardioprotective strategies: Support early in vivo testing of small molecules, biologics, genetic interventions, or RNA-based approaches for cardiac remodeling disorders.

Study Examples

Anemic zebrafish develop cardiac enlargement through cardiomyocyte hypertrophy and hyperplasia.

Sun et al. used anemic zebrafish to investigate workload-induced cardiac hypertrophy in vivo. Reduced oxygen-carrying capacity created chronic hemodynamic stress and led to visible cardiac enlargement. The authors evaluated heart size, ventricular morphology, cardiomyocyte size, and cell proliferation. The model showed that zebrafish cardiac hypertrophy involves both enlargement of existing cardiomyocytes and an increase in cardiomyocyte number, distinguishing it from many mammalian hypertrophy responses.

Fig. 1. Anemic zebrafish show enlarged hearts with increased cardiomyocyte size and number (Sun X, Hoage T, et al., 2009).

mybpc3 knockdown recapitulates hypertrophic cardiomyopathy-like morphology and diastolic dysfunction.

The study generated a zebrafish model of hypertrophic cardiomyopathy by knocking down the myosin-binding protein C homolog, mybpc3. Zebrafish embryos showed increased ventricular wall thickness, atrial dilation, pericardial effusion, impaired ventricular relaxation, and reduced diastolic function. The model reproduced key structural, functional, and arrhythmia-related features of human cardiac hypertrophy and diastolic heart failure, supporting its use for sarcomere gene-related HCM studies.

Fig. 2. mybpc3 knockdown induces ventricular hypertrophy, diastolic dysfunction, and abnormal calcium handling in zebrafish (Chen YH, Pai CW, et al., 2013).

References

1. Sun X, Hoage T, et al. Cardiac hypertrophy involves both myocyte hypertrophy and hyperplasia in anemic zebrafish. PLoS One. 2009;4(8):e6596.
2. Chen YH, Pai CW, et al. Inactivation of Myosin Binding Protein C Homolog in Zebrafish as a Model for Human Cardiac Hypertrophy and Diastolic Dysfunction. Journal of the American Heart Association. 2013;2(5):e000231.